Salter-Cid becomes CSO of Flagship’s new Pioneering Medicines unit; plus Veracyte, Catalent, Zoetis, Gracell, Galecto and more

Flagship Pioneering announced Luisa Salter-Cid as CSO of its new Pioneering Medicines division. Salter-Cid, a 13-year veteran of Bristol Myers Squibb Co. (NYSE:BMY), was most recently CSO at Gossamer Bio Inc. (NASDAQ:GOSS). Salter-Cid will be responsible for developing therapies sourced from Flagship’s portfolio companies as well as building a research capability within the unit.

Marc Stapley will succeed co-founder Bonnie Anderson as CEO at Veracyte Inc. (NASDAQ:VCYT) on June 1 as Anderson becomes executive chairman of the genomic diagnostics company. Stapley, who was chairman and CEO of Helix Opco LLC, will join Veracyte’s board after the company’s annual stockholder meeting on June 7...